Insulin companies commit to CMS program that caps Medicare out-of-pocket insulin costs

The three major U.S. insulin suppliers, Eli Lilly, Novo Nordisk and Sanofi, said they will participate in a program CMS announced Wednesday that will cap out-of-pocket insulin costs for Medicare beneficiaries.

CMS will allow enhanced Medicare Part D plans to provide insulin at a maximum $35 co-pay per month. Medicare beneficiaries

Read the full 517 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers